Unparalleled rare cannabinoid expertise
InMed is a leader in the manufacturing, development and commercialization of rare cannabinoids. Our manufacturing technologies produce several rare cannabinoids for pharmaceutical development and consumer products.
A Portfolio of Rare Cannabinoids for the Health and Wellness Sector
InMed’s subsidiary, BayMedica, is producing a portfolio of rare cannabinoids as raw ingredients for your health and wellness products. We have engineered bioidentical cannabinoids with high purity and consistency, and free of THC. We currently manufacture the rare, minor cannabinoids cannabidivarin (CBDV), cannabichromene (CBC) and cannabicitran (CBT) which are available for wholesale purchase.
We have started production of tetrahydrocannabivarin (THCV), with plans to have this highly sought, minor cannabinoid ready soon for inclusion in a wide variety of health and wellness products.
Unlocking the Therapeutic Potential of Rare Cannabinoids
Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits. InMed has initiated two pharmaceutical programs – a Phase 2 clinical trial for epidermolysis bullosa, a rare genetic skin disease, and has begun preparing to initiate clinical studies in glaucoma following promising preclinical results.
Producing rare cannabinoids for a variety of uses
InMed’s rare cannabinoids are being applied across a spectrum of uses – from pharmaceutical development to wholesale sales to the consumer health and wellness sector. Our pharmaceutical programs include a Phase 2 clinical program in dermatology and a preclinical program in glaucoma. Our division, BayMedica, is the leading large batch producer of wholesale CBC (cannabichromene) cannabinoid for the consumer health and wellness industry. In addition to CBC, we have initiated sales of cannabidivarin (CBDV) and cannabicitran (CBT) and have begun commercial scale production of tetrahydrocannabivarin (THCV) to launch soon. Our portfolio also includes a growing library of patentable rare cannabinoid analogs for development.